In 2011, the United Kingdom's Medicines and Healthcare Products Regulatory Agency granted approval for a clinical trial investigating the safety of using transplanted retinal cells derived from stem cells to treat patients with an advanced type of macular degeneration called Stargardt disease. This is the first trial in patients of a human embryonic stem cell therapy to gain approval from regulators in Europe.
The trial began in August 2015, and the first surgery was described as ‘successful.’
Will another EU member state grant regulatory approval to a clinical trial involving embryonic stem cells by May 31, 2016?
The question resolves positively if by May 31 2016, a credible media report carries a story indicating that this regulatory approval has been met.